Takeda Pharmaceutical Co Ltd 2026 IR
The report outlines Takeda's strategic progress and financial performance for the fiscal year ended March 31, 2026. It highlights the company's advancements in its late-stage pipeline, including regulatory filings for key investigational assets, and its digital transformation initiatives. The report also details Takeda's sustainability commitments, showcasing a 58% reduction in Scope 1 and 2 emissions and a 10% reduction in Scope 3 emissions. Additionally, it emphasizes the company's focus on patient access, employee engagement, and robust corporate governance.
Company: Takeda Pharmaceutical Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2026
Type: IR
Pages: 55
Back to company
Takeda Pharmaceutical Co Ltd
Annual Integrated Report
The report outlines Takeda's strategic progress and financial performance for the fiscal year ended March 31, 2026. It highlights the company's advancements in its late-stage pipeline, including regulatory filings for key investigational assets, and its digital transformation initiatives. The report also details Takeda's sustainability commitments, showcasing a 58% reduction in Scope 1 and 2 emissions and a 10% reduction in Scope 3 emissions. Additionally, it emphasizes the company's focus on patient access, employee engagement, and robust corporate governance.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2026
Reporting Period
Apr 1, 2025 - Mar 31, 2026
Fiscal Year
2025
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Net Zero Target
Employees